← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

Selank × DSIP × 2 of 4 selected View comparison

Selank

Synthetic tuftsin analogue

Remove
VS

DSIP

Neuropeptide

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target SelankDSIP
✓ —
— ✓

What These Compounds Share

Shared research line

All selected compounds are catalogued under Neuro.

Shared pathway tags
CNS

Key Differences

Selank Neurotransmitter-associated is a direct target of Selank that none of the other selected compounds share. A tuftsin-derived neuroactive peptide, distinct from the ACTH-derived Semax.
DSIP Neuroendocrine-associated is a direct target of DSIP that none of the other selected compounds share. A historically sleep-associated neuropeptide with an incompletely established mechanism -- the name does not indicate proven clinical sleep induction.

Compound Detail

Selank
What is it?
A lab-made peptide related to a natural immune signal, studied for calming/CNS effects.
What are people researching/using it for?
Studied for stress and anxiety-related research.
Other uses being trialed
General cognitive-support research
Worth knowing
Human research comes from Russian clinical trials (roughly 60-70 patients per study across three identified trials) comparing Selank against established anxiolytics (phenazepam, medazepam) -- real controlled human evidence, but from a single research tradition with limited independent international replication, and across at least two distinct diagnostic populations (phobic-anxiety/somatoform disorders in one trial; generalized anxiety disorder/neurasthenia in another) that should not be treated as interchangeable.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A tuftsin-derived neuroactive peptide researched in anxiety/stress-related neurobiology.
Heptapeptide · 7 amino acids · Synthetic analogue of tuftsin
Primary Targets & Biological System
CNS / stress signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A synthetic analogue of tuftsin, an immune-signalling tetrapeptide -- but Selank's own research interest is centred on proposed CNS effects rather than tuftsin's immunological role. Multiple neurotransmitter-system and gene-expression mechanisms have been proposed in the literature -- similarly to Semax, no single definitive receptor is asserted, and the mechanistic picture should be read as several parallel hypotheses rather than one confirmed pathway.
Research Areas
Anxiety/stress-related neurobiologyCNS signallingNeurotransmitter systemsImmune-neural signalling
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
Not adequately established
Research Routes
Intranasal (research contexts) (descriptive only — not administration or dosing guidance)
Key Differentiator
A tuftsin-derived neuroactive peptide, distinct from the ACTH-derived Semax.
Considerations
Research Limitations
Human research comes from Russian clinical trials (roughly 60-70 patients per study across three identified trials) comparing Selank against established anxiolytics (phenazepam, medazepam) -- real controlled human evidence, but from a single research tradition with limited independent international replication, and across at least two distinct diagnostic populations (phobic-anxiety/somatoform disorders in one trial; generalized anxiety disorder/neurasthenia in another) that should not be treated as interchangeable.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Generalized anxiety disorder
Russian clinical trials have directly compared Selank with established anxiolytics: one trial (60 patients with phobic-anxiety/somatoform disorders) compared Selank with phenazepam; a separate trial (62 patients with generalized anxiety disorder and neurasthenia, 30 on Selank/32 on medazepam) found similar anxiolytic effects with additional antiasthenic/psychostimulant effects for Selank; a third trial (70 patients) tested Selank added to phenazepam rather than a head-to-head comparison, and found the combination reduced phenazepam's side effects. Same limited-replication caveat applies as with Semax -- this is a real, controlled evidence base, but from a single research tradition.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
Selank · A$69.95 A$79.95
Browse products →
View Research Sources (3) →
[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]
Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (Russian), 2014 · Human Human · 60 patients with phobic-anxiety and somatoform disorders (ICD-10 F40.2-9, F41.1-9, F45.0-1) · PMID 25176261

Russian clinical trial literature, head-to-head vs. phenazepam. Selank showed pronounced anxiolytic and mild nootropic effects, persisting up to a week after the last dose.

Supports: experimental_research, human_administration_status

[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]
Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (Russian), 2008 · Human Human · 62 patients with generalized anxiety disorder and neurasthenia (30 Selank, 32 medazepam) -- a distinct diagnostic population from the phobic-anxiety/somatoform study above · PMID 18454096

Randomized, head-to-head vs. medazepam. Anxiolytic effects similar between arms; Selank additionally showed antiasthenic and psychostimulant effects. Reduced leu-enkephalin half-life correlated with disease severity and improved with Selank treatment.

Supports: experimental_research, human_administration_status

[Optimization of the treatment of anxiety disorders with selank]
Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (Russian), 2015 · Human Human · 70 patients total with anxiety-phobic, hypochondriac and somatoform disorders: 30 on phenazepam monotherapy, 40 on Selank + phenazepam combination · PMID 26356395

NOT a head-to-head Selank-vs-phenazepam comparison -- this tests Selank as an add-on to phenazepam vs. phenazepam alone. Combination produced earlier improvement and reduced phenazepam's side effects (attention/memory impairment, sedation, sexual disturbance) both during and after tranquilizer withdrawal.

Supports: experimental_research

DSIP
What is it?
An older, not-well-understood peptide originally linked to sleep research.
What are people researching/using it for?
Historically studied for sleep -- though the evidence for this is weak and disputed.
Other uses being trialed
General stress-response research -- mechanism remains unclear
Worth knowing
A published human double-blind insomnia study reported statistically significant effects described by the study's own authors as weak, with some possibly attributable to incidental changes in the placebo group rather than a true drug effect. A separate review has questioned the underlying biological interpretation of DSIP altogether. This uncertainty is deliberately not smoothed over here -- its historical name should not be taken to imply clinically proven sleep induction.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A historically sleep-associated neuropeptide with an incompletely established mechanism.
Nonapeptide · 9 amino acids · Originally isolated as an endogenous neuropeptide
Primary Targets & Biological System
Sleep / neuroendocrine signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
Despite being named for an early finding of sleep-associated activity, DSIP does not have a definitively established receptor or mechanism in the literature. The "Neuroendocrine-associated" label shown above is not a confirmed binding target -- it reflects only the broad research area its proposed effects have touched on, because no specific receptor has been reliably confirmed for DSIP. A 2006 review specifically questioned the biological basis for treating DSIP as a coherent, receptor-mediated "sleep peptide" at all. This mechanistic uncertainty is a central, not peripheral, fact about this compound.
Research Areas
Sleep physiologyNeuroendocrine signallingStress physiologyCNS research
Research Profile
Human administration: Limited Preclinical: Available
Pharmacokinetics
Not adequately established
Research Routes
Not established in humans (descriptive only — not administration or dosing guidance)
Key Differentiator
A historically sleep-associated neuropeptide with an incompletely established mechanism -- the name does not indicate proven clinical sleep induction.
Considerations
Research Limitations
A published human double-blind insomnia study reported statistically significant effects described by the study's own authors as weak, with some possibly attributable to incidental changes in the placebo group rather than a true drug effect. A separate review has questioned the underlying biological interpretation of DSIP altogether. This uncertainty is deliberately not smoothed over here -- its historical name should not be taken to imply clinically proven sleep induction.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
DSIP · A$84.95 A$99.95
Browse products →
View Research Sources (2) →
Review questioning the biological interpretation of DSIP
Review / secondary literature · PMID 16539679

Supports: mechanism_summary, research_limitations

Human double-blind insomnia study
Human Human · PMID 1299794

Authors reported the statistically significant effects were weak, with some possibly attributable to incidental placebo-group changes.

Supports: research_limitations, human_administration_status

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.